UConn Health

health.uconn.edu

Total trials

185

Active

27

Phase 3

9

Total enrollment

42,346

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Gadopiclenol1
Gadobutrol1
Levothyroxine1
Levothyroxine/Liothyronine once daily1
Levothyroxine/Liothyronine twice daily1
Mitoquinone Mesylate1
Amino acid supplement1

Next readouts

  • 2025-09
  • 2026-06-30
  • 2027-03-01
  • 2027-12-31

Top conditions

  • Substance Abuse11
  • Alcoholism10
  • Alcohol Abuse9
  • Contingency Management8
  • Alcohol Dependence6
  • Gambling5
  • Nicotine Dependence5
  • Cigarette Smoking5

Frequently asked questions about UConn Health

How many clinical trials does UConn Health have on ClinicalTrials.gov?
UConn Health is listed as the lead sponsor on 185 clinical trials in ClinicalTrials.gov, 27 of which are currently active (recruiting, enrolling, or ongoing).
How many of UConn Health's trials are in Phase 3?
9 of UConn Health's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does UConn Health focus on?
UConn Health's most-studied conditions on ClinicalTrials.gov are Substance Abuse, Alcoholism, Alcohol Abuse, Contingency Management, Alcohol Dependence.
When are UConn Health's next clinical trial readouts?
UConn Health has 4 upcoming primary-completion readouts tracked here; the soonest is “A Targeted Amino Acid Supplement for People With Parkinson's Disease”, expected around 2025-09.